Congo-Kinshasa: Ebola - DRC Gets 70,000 Ervebo Vaccine Doses As Bundibugyo Outbreak Worsens
The Democratic Republic of the Congo has received 70,000 doses of the Ervebo Ebola vaccine to combat an outbreak of the Bundibugyo virus. A portion of these doses will be used in a Phase III clinical trial to determine the vaccine's efficacy against this specific virus strain.
Why it matters
The trial is critical for public health, as it addresses the uncertainty regarding whether existing Ebola vaccines can protect against different viral species.
DRC receives 70,000 Ervebo vaccine doses, with 20,000 for a Phase III trial against Bundibugyo virus and 50,000 for frontline and health workers.
The Democratic Republic of the Congo (DRC) has received an initial allocation of 70,000 doses of the Ervebo Ebola vaccine to support the response to the ongoing Bundibugyo virus disease outbreak.
The World Health Organisation (WHO) and the Africa Centres for Disease Control and Prevention (Africa CDC) disclosed this in a joint statement on Thursday.
The allocation followed a request by the DRC government last week for vaccines from the global Ebola virus disease vaccine stockpile managed by the International Coordinating Group on Vaccine Provision (ICG).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in